The evidence from this review suggests that there are no clinically meaningful BP lowering differences between available ARBs. The BP lowering effect of ARBs is modest and similar to ACE inhibitors as a class; the magnitude of average trough BP lowering for ARBs at maximum recommended doses and above is -8/-5 mmHg.  Furthermore, 60 to 70% of this trough BP lowering effect occurs with recommended starting doses. The review did not provide a good estimate of the incidence of harms associated with ARBs because of the short duration of the trials and the lack of reporting of adverse effects in many of the trials.
Losartan with hydrochlorothiazide in the treatment of hypertension.
To review the efficacy and safety of losartan and hydrochlorothiazide compared to losartan alone, hydrochlorothiazide alone or placebo in the treatment of mild to moderate hypertension in a clinical trial.
                A randomly allocated, placebo-controlled, double-blind parallel study was performed in 40 clinical centers throughout the United States. A total of 703 males and females aged 18-75 years with a sitting diastolic blood pressure of 95-115 mmHg entered the trial and 604 completed the 12-week protocol. The participants were randomly assigned to concomitant therapy once a day with: (1) 50 mg losartan and 6.25 mg hydrochlorothiazide, (2) 50 mg losartan and 12.5 mg hydrochlorothiazide, (3) 50 mg losartan alone, (4) 12.5 mg hydrochlorothiazide alone or (5) placebo. All participants were followed for 12 weeks.
                At baseline, mean trough sitting diastolic blood pressure was 100.9-101.7 mmHg, with no significant difference between treatment groups. Sitting diastolic blood pressure fell 4.0 mmHg with placebo, 7.2 mmHg with 12.5 mg hydrochlorothiazide, 7.2 mmHg with 50 mg losartan, 9.3 mmHg with 50 mg losartan + 6.25 mg hydrochlorothiazide, and 13.2 mmHg with 50 mg losartan + 12.5 mg hydrochlorothiazide. The fall in mean trough sitting systolic blood pressure was 2.4, 9.3, 10.7, 12.0 and 17.9 mmHg for the respective groups. After subtracting the placebo effect, the reductions in blood pressure induced by losartan and hydrochlorothiazide were additive for both sitting diastolic and systolic blood pressures and approximately equaled the reduction seen with the combination of losartan and hydrochlorothiazide. There were no significant differences in adverse events between treatment groups.
                The concomitant administration of 50 mg losartan + 12.5 mg hydrochlorothiazide produced additive falls in sitting diastolic and systolic blood pressures which were greater than that achieved with either drug alone. On the basis of the adverse effects reported, the combination was well tolerated.